UPDATE: Relypsa's (RLYP) Veltassa Approved by FDA
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/7/2026
- Rivian Automotive (RIVN) files for 75M share offering
- Rivian offers Q2 2026 revenue outlook, cash position grows
- Fiserv president resigns, interim leaders named for financial unit
- Nokia OYJ (NOKIA:FH) (NOK) PT Raised to EUR14 at Kepler Cheuvreux
- Coursera plans layoffs after Udemy merger, estimates $8M-$11M in costs
Oppenheimer Survey of Patient Therapy Combinations Show Relypsa (RLYP) Concern Overblown
October 23, 2015 8:32 AM EDTOppenheimer Biotech analyst, Ling Wang, published a note highlighting a possible overreaction to Relypsa (NASDAQ: RLYP) conference call which discussed Veltassa being required to post a warning label on bottles. She discussed a market research survey that indicates the problem may only impact 2% to 5% of the population making the 25% selloff overdone. Veltassa is expected to be... More
Relypsa (RLYP) Pares Gains on Concerns about Veltassa's Label
October 22, 2015 8:14 AM EDTRelypsa (NASDAQ: RLYP) declined pre-market Thursday, reversing earlier gains following FDA approval of Veltassa. Declines appear related to concerns about the drug's label. Analysts at Morgan Stanley reportedly described the label as "highly restrictive" and said it will probably limit demand.
... MoreOppenheimer Remains Bullish on Relypsa (RLYP) Following FDA's Veltassa Approval
October 22, 2015 6:49 AM EDTOppenheimer reiterated an Outperform rating and $55.00 price target on Relypsa, Inc. (NASDAQ: RLYP) after the FDA approved Veltassa once-daily for the treatment of hyperkalemia. Veltassa is expected to be available in the US by the first week of January 2016.
Analyst Ling Wang commented,... More
Relypsa (RLYP) halted with news pending
October 21, 2015 5:18 PM EDTRelypsa (NASDAQ: RLYP) trading halted with news pending.
... More